RarinJinda Wellness Spa announced Best Luxury Destination Spa - Thailand at World Luxury Spa Awards 2012

Food and Healthcare Press Releases Monday May 21, 2012 09:49
Bangkok--21 May--RarinJinda Wellness Spa

RarinJinda Wellness Spa has been announced as the Best Luxury Destination Spa - Thailand at the World Luxury Spa Awards 2012. This prestigious award is the first award for the year of 2012 for RarinJinda Wellness Spa and added to the many awards already received both locally and globally.

The World Luxury Spa Awards™ celebrate the spa industry with 12 spa categories. Open to luxury spas in the respective categories, the World Luxury Spa Awards™ are recognized and respected on the global front by the public and media at large and are universally acknowledged as the world’s leading awards initiative for luxury spas. Competing spas in 2012 included small sized privately owned spas to globally renowned spa groups. The winners and finalists were selected by means of the annual voting process where thousands of spa guests worldwide have been given the opportunity to vote online. Official voting closed on the 7th of May and the response and comments from voters was phenomenal. Thousands of votes came in from across the globe and as a result key brands and independent spas were rewarded for their extraordinary efforts..

RarinJinda Wellness Spa is one of Thailand`s leading wellness spa, located in Bangkok, Chiang Mai and Phuket, with expertised therapists and latest spa technologies. It offers clients wellness, good health and luxurious pampering in a spa sanctuary. It is an urban spa fully equipped with all of the latest spa technology and facilities at high international standards, yet deeply rooted in the Thai massage and healing traditions. RarinJinda is an oasis of health and wellness. Facilities include state-of-the-art Indoor heated Hydrotherapy pool, Vichy Shower, Hydrotherapy Tub, Whirlpool with Chromotherapy, Rainforest Steam and Sauna. Alternative Medicine Specialist and nurses are also available on premise to provide consultation and guidance

Source: www.luxuryhotelawards.com/winners/2012-spa-awards
ติดต่อ:
Mr. Narun Wiwattanakrai, Asst. Executive Director (Marketing & PR) T. 02 641 6619-20 or narun@rarinjinda.com
Ms. Ratpalee Suphawatanakiat, PR Manager, T. 02 641 6619-20 or ratpalee@bloomingspa.com

Latest Press Release

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

The Mall Shopping Center and Government Savings Bank Co-host The Mall Health Beauty Expo 2018

The Mall Shopping Center, Government Savings Bank, leading hospitals and health institutions are co-hosting an annual grand event, "The Mall Health & Beauty Expo 2018" on June 28 – July 4, 2018 at the Grand Hall, G Floor, The Mall Bangkapi....

Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

ASCO Abstract # ERBITUX(R) (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814...

Related Topics